Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers

Sergey V. Kozin(Sechenov University), Igor Garkavtsev(Massachusetts General Hospital)

Oncotarget

November 26, 2017

10.18632/oncotarget.22660

Cited by 31

Related Papers

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

|Nature Medicine|2004|2k

Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients

|Journal of Clinical Oncology|2005|419

Erratum: CORRIGENDUM: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

|Nature Medicine|2004|21